Interleukins: Clinical Pharmacokinetics and Practical Implications

Clinical Pharmacokinetics

Volumn 21, Issue 4, 1991, Pages 274-284

  Bocci, Velio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; DRUG METABOLISM; DRUG TOXICITY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; RECTAL DRUG ADMINISTRATION; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

ANIMAL; DRUG ADMINISTRATION ROUTES; HUMAN; INTERLEUKINS; MICE; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0025940020     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199121040-00004     Document Type: Review

References (98)

1. Studies on the anti-tumor efficacy of systematically administered recombinant tumor necrosis factor against several murine tumors in vivo
2. Carbohydrate — specific receptors of the liver
3. The role of aspartic and cysteine proteinases in albumin degradation by rat kidney cortical lysosomes
4. Autoantibodies to cytokines: friends or foes
5. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo
6. Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects
7. Neuromodulative actions of cytokines
8. Phase I study of recombinant tumor necrosis factor in cancer patients
9. Distribution of interferon in body fluids and tissues
10. What is the role of carbohydrates in interferons?
11. Evaluation of routes of administration of interferon in cancer: a review and a proposal
12. Administration of interferon at night may increase its therapeutic index
13. Immunomodulators as local hormones: new insights regarding their clinical utilization
14. Distribution, catabolism and pharmacokinetics of interferons
15. Metabolism of protein anticancer agents
16. Roles of interferon produced in physiological conditions: a speculative review
17. Central nervous system toxicity of interferons and other cytokines
18. Catabolism of therapeutic proteins and peptides with implications for drug delivery
19. Is interferon effective after oral administration? The state of the art
20. Renal metabolism of rabbit serum interferon
21. The kidney is the main site of interferon catabolism
22. Studies on tumor necrosis factor (TNF)-1. Pharmacokinetics of human recombinant TNF in rabbits and monkeys after intravenous administration
23. Catabolic sites of human interferon-γ
24. Pulmonary catabolism of interferons: alveolar absorption of 125l-labeled human interferon alpha is accompanied by partial loss of biological activity
25. Pharmacokinetics of human lymphoblastoid interferon in rabbits
26. Metabolic behaviour of recombinant interferons β
27. 2-microglobulin as a cytokine binding plasma protein
28. The major regulator of acute-phase protein synthesis in man and rat
29. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat
30. Systemic administration of recombinant human interleukin-2 in mice
31. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth
32. Structures of the major carbohydrates of natural human interleukin-2
33. Phase I clinical trial of recombinant human tumor necrosis factor
34. The fate of interleukin-2 after in vivo administration
35. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
36. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients
37. Pharmacokinetics and tissue distribution of recombinant human tumor necrosis factor-α in mice
38. Pharmacokinetics of recombinant human tumor necrosis factor-α in rats: effects of size and number of doses and nephrectomy
39. Pharmacokinetics of murine tumor necrosis factor
40. Purification and biochemical characterization of a soluble human interferon γ receptor expressed in Escherichia coli
41. Studies on the in vivo production of a lymphokine activity, interleukin 3 (IL-3) elaborated by lymphocytes and a myeloid leukaemic line in vitro and the fate of IL-3 dependent cell lines
42. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells
43. Clinical pharmacokinetics
44. Toxic effects of recombinant tumor necrosis factor in suckling mice
45. Interleukin-6: possible implications in human diseases
46. 2-macroglobulin
47. Sarcolectin: an interferon antagonist extracted from hamster sarcomas and normal muscles
48. Structure of tumour necrosis factor
49. Rate of clearance of interleukin-1 from the blood of normal and nephrectomized rats
50. Rate of clearance of circulating leukocytic endogenous mediator in the rat
51. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol
52. Interleukin 1 activitiy in normal human urine
53. Phase I study of recombinant human tumor necrosis factor
54. Fate and biological action of human recombinant interleukin 1β in the rat in vivo
55. 4
56. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers
57. Pharmacokinetics of recombinant interleukin 2 in humans
58. Somnogenic cytokines and models concerning their effects on sleep
59. Serum inhibitors of interleukin-2
60. Clearance and tissue distribution of recombinant human interleukin 1β in rats
61. New methods of drug delivery
62. Native interleukin 1 inhibitors
63. Cardiorespiratory effects of immunotherapy with interleukin-2
64. An inhibitor of interferon action: 1. Physical association of the inhibitor with interferon-gamma
65. In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2
66. Systemic administration of interleukin-2 in humans
67. Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor
68. 2-macroglobulin as a carrier protein for IL-6
69. The consequences of excess levels of haemopoietic growth factors
70. Tissue localization and fate in mice of injected multipotential colony-stimulating factor
71. Transcytosis of albumin in capillary endothelium
72. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease
73. Antitumor activity of recombinant interleukin 6 in mice
74. Clearance of interleukin 2 from the blood of normal and T cell-depleted mice
75. The distribution and clearance of radiolabeled human interleukin-1 beta in mice
76. Soluble cytokine receptors are present in normal human urine
77. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice
78. Studies on tumor necrosis factor (TNF): III. Plasma disappearance curves after intramuscular, subcutaneous, intraperitoneal and oral administration of human recombinant TNF
79. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice
80. Studies on tumor necrosis factor (TNF): II Metabolic fate and distribution of human recombinant TNF
81. Biological activity of recombinant human interleukin-2 produced in escherichia coli
82. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 alone
83. Drug delivery systems and routes of administration of peptide and protein drugs
84. A pilot study of intralymphatic interleukin-2: II. Clinical and biological effects
85. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor
86. A pilot study of intralymphatic interleukin-2: 1. Cytotoxic and surface marker changes of peripheral blood lykmphocytes
87. Hypothalamic neuronal responses to cytokines
88. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome
89. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion: a phase I and pharmacologic study
90. Tumor necrosis factor causes increased pulmonary permeability and edema
91. Passage of immunomodulators across the blood-brain barrier
92. Sites of clearance of leucocyte pyrogen in the rabbit
93. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
94. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone
95. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
96. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma
97. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models